SEC Form 4 · accession 0001816952-26-000005
Mineralys Therapeutics, Inc. · MLYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daphne Karydas
Director
Period of report
Sep 15, 2026
Accepted (ET)
Sep 17, 2026 · 5:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001933414
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 15, 2026 | M | 3,000 | $12.02 | A | 9,200 | D | |
| Common Stock | Sep 15, 2026 | S | 3,000 | $28.58 | D | 6,200 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2 | $12.02 | Sep 15, 2026 | M | 3,000 | D | — | Sep 13, 2033 | Common Stock | 3,000 | 35,000 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025.
- F2The stock option vests in 36 monthly installments beginning on October 13, 2023.